Recent Updates — NUVB-WT

Nuvation Bio Inc. reported second quarter 2026 financial results on August 6, 2026, achieving total revenue of $31.7 million, which included $23.2 million in net product revenue for its ROS1 inhibitor IBTROZI (taletrectinib) and $8.5 million in collaboration and license agreements revenue. The company reported a net loss of $62.8 million, or $(0.18) per share on a basic and diluted basis, compared to a net loss of $59.0 million in the prior year period. Research and development expenses increased to $30.7 million from $27.4 million, while selling, general, and administrative expenses rose to $42.6 million from $38.5 million. As of June 30, 2026, Nuvation Bio held cash, cash equivalents, and marketable securities totaling $661.0 million, with an additional $36.5 million in net proceeds secured in July 2026 from the exercise of convertible senior notes overallotment options. The company operates in the biotechnology industry, focusing on developing oncology therapies.

Nuvation Bio Inc. completed a $250.0 million public offering of 0.75% Convertible Senior Notes due 2032, and on July 6, 2026, the underwriters exercised their over-allotment option to issue an additional $37.5 million in Notes. The total aggregate principal amount of Notes sold was $287.5 million, with estimated net proceeds of approximately $277.6 million. Nuvation Bio Inc. is a biotechnology company focused on developing and commercializing oncology-related therapies.